NASDAQ:TRVI

Trevi Therapeutics - TRVI Stock Forecast, Price & News

$1.54

0.00 (0.00%)

(As of 09/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $1.43
▼
$1.79
50-Day Range: $1.54
▼
$4.28
52-Week Range: $0.46
▼
$4.68

Volume: 840,684 shs
Average Volume: 327,148 shs
Market Capitalization: $67.87 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.67

Trevi Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 592.6% Upside
$10.67 Price Target
Short Interest: Healthy
0.22% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$197,700 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.62) to ($0.67) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Medical Sector

387th out of 1,095 stocks

Pharmaceutical Preparations Industry

172nd out of 547 stocks

3.5

Analyst's Opinion

Consensus Rating
Trevi Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.67, Trevi Therapeutics has a forecasted upside of 592.6% from its current price of $1.54.
Amount of Analyst Coverage
Trevi Therapeutics has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.22% of the outstanding shares of Trevi Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Trevi Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Trevi Therapeutics has recently decreased by 9.85%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Trevi Therapeutics does not currently pay a dividend.
Dividend Growth
Trevi Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TRVI.

2.7

News and Social Media Coverage

News Sentiment
Trevi Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Trevi Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 6 people have searched for TRVI on MarketBeat in the last 30 days. This is a decrease of -54% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Trevi Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $197,700.00 in company stock.
Percentage Held by Insiders
39.52% of the stock of Trevi Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Trevi Therapeutics are expected to decrease in the coming year, from ($0.62) to ($0.67) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Trevi Therapeutics is -1.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Trevi Therapeutics is -1.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Trevi Therapeutics has a P/B Ratio of 2.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Trevi Therapeutics (NASDAQ:TRVI) Stock

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Receive TRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TRVI Stock News Headlines

September 23, 2022 | au.investing.com

After-Hours Movers: Spectrum Pharm Sinks on Negative FDA Panel, Costco Dips on...

September 23, 2022 | finance.yahoo.com

/C O R R E C T I O N -- Trevi Therapeutics, Inc./

September 23, 2022 | finance.yahoo.com

Trevi Therapeutics Announces Proposed Public Offering

September 19, 2022 | finance.yahoo.com

Trevi Therapeutics Shares Jump After Complete Data From Chronic Cough Trial

September 19, 2022 | markets.businessinsider.com

Trevi Reports Positive Results From Full Set Of Subjects From CANAL Trial Of Haduvio

September 19, 2022 | finance.yahoo.com

Trevi Therapeutics Announces Positive Data from Full Set of Subjects in Phase 2 CANAL Trial of Haduvio™ in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis

September 14, 2022 | finance.yahoo.com

Is AVEO Pharmaceuticals (AVEO) Outperforming Other Medical Stocks This Year?

September 11, 2022 | seekingalpha.com

Trevi Therapeutics: Moving Forward

August 30, 2022 | finance.yahoo.com

Trevi Therapeutics to Host Virtual R&D Day on September 19, 2022

August 16, 2022 | nasdaq.com

What Type Of Shareholders Own The Most Number of Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares?

August 11, 2022 | finance.yahoo.com

Trevi Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

August 8, 2022 | msn.com

Gloria Trevi On the Highs and Lows of Her 40-Year Career — And What Has Remained Consistent In Her Music

August 4, 2022 | finance.yahoo.com

Trevi Therapeutics to Report Q2 2022 Financial Results and Provide a Corporate Update on August 11, 2022

July 19, 2022 | finance.yahoo.com

Is Trevi Therapeutics, Inc.'s (NASDAQ:TRVI) Shareholder Ownership Skewed Towards Insiders?

July 14, 2022 | finance.yahoo.com

Traders News Source Senior Editor Mark Roberts Interviews Jennifer Good CEO of Trevi Therapeutics

July 6, 2022 | uk.finance.yahoo.com

Which way is the Trevi Therapeutics share price trending?

July 3, 2022 | americanbankingnews.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Short Interest Update

June 30, 2022 | finance.yahoo.com

Why Did Needham Lift Price Target For Trevi?

June 30, 2022 | stocknews.com

Wall Street Predicts These 2 Sub-$5 Stocks Have More Than 200% Upside

June 29, 2022 | finance.yahoo.com

Why Trevi Therapeutics Shares Trading Higher Today?

June 29, 2022 | investorplace.com

Trevi Therapeutics (TRVI) Stock Spikes 20% on Positive Clinical Data

June 29, 2022 | investorplace.com

Trevi Therapeutics (TRVI) Spikes 20% on Positive Clinical Data

June 29, 2022 | seekingalpha.com

Trevi surges 29% as trial for pain therapy meets key goals in skin disorder

June 29, 2022 | finance.yahoo.com

Trevi Therapeutics Reports Positive Results from the Ph2b/3 PRISM Trial of Haduvio™ in the Treatment of Prurigo Nodularis

June 29, 2022 | finance.yahoo.com

Trevi's stock gains 38% after announcing positive data for skin-disease drug

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive TRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TRVI Company Calendar

Last Earnings: 8/11/2022
Today: 10/02/2022
Next Earnings (Estimated): 11/09/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TRVI
CUSIP: N/A
CIK: 1563880
Web: www.trevitherapeutics.com
Phone: (203) 304-2499
Fax: N/A
Employees: 24
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $10.67
High Stock Price Forecast: $12.00
Low Stock Price Forecast: $10.00
Forecasted Upside/Downside: +592.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.00)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-33,940,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -125.34%
Return on Assets: -68.53%

Debt

Debt-to-Equity Ratio: 0.09
Current Ratio: 5.18
Quick Ratio: 5.18

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.66 per share
Price / Book: 2.33

Miscellaneous

Outstanding Shares: 44,070,000
Free Float: 26,654,000
Market Cap: $67.87 million
Optionable: Not Optionable
Beta: 0.20

Key Executives

Ms. Jennifer L. Good (Age 57)
Co-Founder, CEO, Pres & Director
Comp: $731.41k

Dr. Thomas R. Sciascia (Age 69)
Co-Founder & Chief Medical Officer
Comp: $499.65k

Dr. William P. Forbes Pharm. D. (Age 60)
Pharm.D., Chief Devel. Officer
Comp: $596.74k

Ms. Lisa Delfini (Age 52)
Chief Financial Officer

Mr. Christopher Galletta (Age 44)
Controller & Chief Accounting Officer

Mr. Frank P. Muscolo (Age 65)
Exec. Officer

Ms. Danine Summers (Age 64)
VP of Medical Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TRVI Stock - Frequently Asked Questions

Should I buy or sell Trevi Therapeutics stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevi Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TRVI shares.
View TRVI analyst ratings or view top-rated stocks.
What is Trevi Therapeutics' stock price forecast for 2022?: 3 Wall Street research analysts have issued 12-month price targets for Trevi Therapeutics' shares. Their TRVI share price forecasts range from $10.00 to $12.00. On average, they predict the company's share price to reach $10.67 in the next twelve months. This suggests a possible upside of 592.6% from the stock's current price.
View analysts price targets for TRVI or view top-rated stocks among Wall Street analysts.
How have TRVI shares performed in 2022?: Trevi Therapeutics' stock was trading at $0.7822 at the beginning of the year. Since then, TRVI shares have increased by 96.9% and is now trading at $1.54.
View the best growth stocks for 2022 here.
When is Trevi Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our TRVI earnings forecast.
How were Trevi Therapeutics' earnings last quarter?: Trevi Therapeutics, Inc. (NASDAQ:TRVI) announced its quarterly earnings data on Thursday, August, 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.07.

What other stocks do shareholders of Trevi Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Trevi Therapeutics investors own include Trevena (TRVN), Diffusion Pharmaceuticals (DFFN), Fulcrum Therapeutics (FULC), Genocea Biosciences (GNCA), Marker Therapeutics (MRKR), VYNE Therapeutics (VYNE), Akero Therapeutics (AKRO), Aldeyra Therapeutics (ALDX), AzurRx BioPharma (AZRX) and Chimerix (CMRX).
When did Trevi Therapeutics IPO?: (TRVI) raised $70 million in an initial public offering on Tuesday, May 7th 2019. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets acted as the underwriters for the IPO and Needham & Company was co-manager.
What is Trevi Therapeutics' stock symbol?: Trevi Therapeutics trades on the NASDAQ under the ticker symbol "TRVI."
How do I buy shares of Trevi Therapeutics?: Shares of TRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Trevi Therapeutics' stock price today?: One share of TRVI stock can currently be purchased for approximately $1.54.
How much money does Trevi Therapeutics make?: Trevi Therapeutics (NASDAQ:TRVI) has a market capitalization of $67.87 million. The company earns $-33,940,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis.
How can I contact Trevi Therapeutics?: Trevi Therapeutics' mailing address is 195 CHURCH STREET 14TH FLOOR, NEW HAVEN CT, 06510. The official website for the company is www.trevitherapeutics.com. The company can be reached via phone at (203) 304-2499 or via email at peter.vozzo@westwicke.com.

This page (NASDAQ:TRVI) was last updated on 10/2/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Trevi Therapeutics - TRVI Stock Forecast, Price & News

Trevi Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Trevi Therapeutics (NASDAQ:TRVI) Stock

TRVI Stock News Headlines

TRVI Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

TRVI Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™